Targeting Tumors with High Mutational Burden: Treating Patients with Advanced Non-Melanoma Skin Cancers
June 6, 2023
June 6, 2024
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
- Nurses — 1.0 Contact Hours
Nursing learners, view this Learner Notification prior to starting this activity.
This activity is designed to meet the educational needs of global oncologists, dermatologists, Mohs surgeons, and the multidisciplinary care team who care for patients with advanced or metastatic basal cell or cutaneous squamous cell carcinomas.
This enduring activity will increase the target clinician’s knowledge base on new systemic immune therapies for the treatment of patients with non-melanoma skin cancer (NMSC); enhance their ability to identify and manage side effects associated with new immunotherapies for the treatment of patients with advanced basal cell carcinoma or cutaneous squamous cell carcinoma; and improve their ability to coordinate care and cooperation across the multidisciplinary care team to optimize outcomes in patients with NMSC.
Upon the completion of this program, attendees should be able to:
- Incorporate immune checkpoint inhibitor therapy data into the management of patients with metastatic or locally advanced cutaneous squamous cell carcinoma
- Review the immune therapy data for patients with either metastatic or locally advanced basal cell carcinoma in the second-line setting
- Recognize and manage the treatment related adverse events associated with immune checkpoint inhibitor therapy in patients with non-melanoma skin cancers
- Describe the multidisciplinary team approach in the management of patients with locally advanced or metastatic basal cell or cutaneous squamous cell carcinomas
Reinhard Dummer, MD
Professor and Vice Chairman
Department of Dermatology
University of Zurich Hospital
Michael R. Migden, MD
Professor Department of Dermatology and Department of Head and Neck Surgery
Division of Internal Medicine
University of Texas MD Anderson Cancer Center
Vishal A. Patel, MD
Director of Cutaneous Oncology
Director of Dermatologic Surgery
Associate Professor of Dermatology and Medicine/Oncology
George Washington University School of Medicine & Health Sciences
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
Physician Credit Designation Statement
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NURSES (ANCC) CREDIT DESIGNATION
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURES OF CONFLICTS OF INTEREST:
Dr. Dummer has intermittent, project focused consulting and/or advisory relationships with Novartis, Merck Sharp & Dhome (MSD), Bristol-Myers Squibb (BMS), Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi, Catalym, Second Genome, Regeneron, Alligator, T3 Pharma, MaxiVAX SA, Pfizer, and touchlME outside the submitted work.
Dr. Migden has received consulting fees from Regeneron, Replimune, Sun Pharmaceuticals, and Stamford Pharmaceuticals.
Dr. Patel has received consulting fees from Regeneron, Sanofi, PhD Biosciences, Almirall, and Jounce Therapeutics. He is on the Speakers Bureau for Regeneron, Sanofi, and Almirall, and has ownership interests in Avstera Therapeutics, Lazarus AI, and Science 37.
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed. The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer. The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they partner have with ineligible companies related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
Chris Drury, MA, MS, MBA, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group has nothing to disclose.
Russie Allen, Accreditation and Outcomes Manager for Med Learning Group has nothing to disclose.
Felecia Beachum, Program Manager for Med Learning Group has nothing to disclose.
Naomi De Brito, Program Coordinator for Med Learning Group has nothing to disclose.
INSTRUCTIONS FOR PARTICIPATION AND CREDIT:
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the enduring activity.
- Complete the online post-test and evaluation
You will receive your certificate as a downloadable file.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group at [email protected]